What the Disclosure Memorandum covers.

This is a one-page orientation. It is not the Memorandum itself, and it does not summarize it in full — every investor receives the complete document and must acknowledge it before signing.

Why it exists

E4L, Inc. is a newly formed company that acquired the assets, subsidiaries, customer base and data of the former XPO Health / NES Health group, and it is raising capital in parallel with completing that restructuring. That is a deliberate, disclosed choice. The Disclosure Memorandum is how the Company puts the entire story — including the parts an investor should scrutinize — in writing, in one place, before anyone commits.

What it contains

• The restructuring, explained plainly. How the company was formed, what it acquired and from whom, and the solvent wind-down of the UK entity — full detail in the Memorandum.
• A chain-of-title status table. Every transfer step — the subsidiaries, the IP assignments, the customer data, the contribution into the US company — with its current status as the transfers complete.
• Risk factors, in full. Early-stage company with no operating history; wellness-claims and regulatory risk; key-person dependence on the founder; related-party transactions; chain-of-title and restructuring risk; illiquidity; QSBS uncertainty; financing risk; control, conversion and dilution; and ordinary business risks.
• Regulatory standing — a clean track record. The Company presents its products as general-wellness offerings that make structure/function and wellbeing claims only — not medical devices, and with no claim to diagnose, treat, cure or prevent disease. Its regulatory history is clean: across 20+ years of commercial history, the acquired products have passed three FDA inspections with no issues — including an in-person infoceuticals inspection and repeated, stricter customs/FDA import reviews — and BWS has never been questioned (its claims are deliberately non-medical). The miHealth handheld is in the final stages of FDA over-the-counter clearance for pain relief — a positive milestone in progress — and the GEM is positioned as a performance/wellness product. Regulatory exposure is minimal. (The signed Memorandum retains a full regulatory risk factor, as a Reg D document should.)
• Related-party transactions, disclosed in full. Massey Developments' contribution of the acquired assets, IP and customer base as founder equity — its holding company taking $3.2M of Class B Preferred (pegged to cost, junior), with no repayable note or royalty; the equity structure — a single 1× non-participating preference for cash actually invested (new investors' Class A senior on conversion, the founder's own $3.2M and Kitty Stoneburner's ~$1.6M Class B junior, nobody double-dipping) and the founder's Founder Common (ordinary one-vote common economics; his control comes from his majority ownership plus the right to designate all three seats of the three-member board (currently Harry Massey, Susan Kichuk and one open seat), not a super-voting multiple); Kitty Stoneburner's (Healing Frequencies LLC) two mutually exclusive outcomes — restricted Class B Preferred if she stays, or the contingent share-buyback (Put) if she exercises it, never both — with the founder's personal guarantee and backstop of the Put (if exercised, funded by a separate ~$2M raise and/or Harry's backstop loan, not from the SAFE investors' capital); the Company's outright ownership of the FIELD diagnostic platform and its products through the acquired NES Health LLC and Energy 4 Life LLC subsidiaries (no licence caveat); the discretionary goodwill grants; and the phantom-equity rights.
• The investor acknowledgment. A signed confirmation that the investor has read it, is not relying on any legacy-group historical figures, and understands the risks.

The honest headline

How it fits the deal

The Memorandum supplements — and, where inconsistent, supersedes — any presentation, conversation or other material an investor has received, including this website. Nothing in the Company's public materials, webinars or films forms part of the offering.